Viral infection reveals hidden sharing of TCR CDR3 sequences between individuals.

LCMV (lymphocytic choriomeningitis virus) TCR - T cell receptor effector T cells epitope-specific T cell severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2023
Historique:
received: 02 04 2023
accepted: 16 05 2023
medline: 19 6 2023
pubmed: 16 6 2023
entrez: 16 6 2023
Statut: epublish

Résumé

The T cell receptor is generated by a process of random and imprecise somatic recombination. The number of possible T cell receptors which this process can produce is enormous, greatly exceeding the number of T cells in an individual. Thus, the likelihood of identical TCRs being observed in multiple individuals (public TCRs) might be expected to be very low. Nevertheless such public TCRs have often been reported. In this study we explore the extent of TCR publicity in the context of acute resolving Lymphocytic choriomeningitis virus (LCMV) infection in mice. We show that the repertoire of effector T cells following LCMV infection contains a population of highly shared TCR sequences. This subset of TCRs has a distribution of naive precursor frequencies, generation probabilities, and physico-chemical CDR3 properties which lie between those of classic public TCRs, which are observed in uninfected repertoires, and the dominant private TCR repertoire. We have named this set of sequences "hidden public" TCRs, since they are only revealed following infection. A similar repertoire of hidden public TCRs can be observed in humans after a first exposure to SARS-COV-2. The presence of hidden public TCRs which rapidly expand following viral infection may therefore be a general feature of adaptive immunity, identifying an additional level of inter-individual sharing in the TCR repertoire which may form an important component of the effector and memory response.

Identifiants

pubmed: 37325645
doi: 10.3389/fimmu.2023.1199064
pmc: PMC10266217
doi:

Substances chimiques

Receptors, Antigen, T-Cell 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1199064

Informations de copyright

Copyright © 2023 Mark, Reich-Zeliger, Greenstein, Biram, Chain, Friedman and Madi.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

J Virol. 2005 Aug;79(16):10514-27
pubmed: 16051844
Blood. 2009 Nov 5;114(19):4099-107
pubmed: 19706884
Elife. 2017 Jul 21;6:
pubmed: 28731407
Bioinformatics. 2017 Nov 15;33(22):3645-3647
pubmed: 29036507
Front Immunol. 2018 Jul 24;9:1618
pubmed: 30087674
iScience. 2023 Jun 16;26(6):106937
pubmed: 37275518
PLoS Comput Biol. 2021 Jan 19;17(1):e1008486
pubmed: 33465095
Philos Trans R Soc Lond B Biol Sci. 2000 Mar 29;355(1395):373-9
pubmed: 10794058
Genome Res. 2014 Oct;24(10):1603-12
pubmed: 25024161
Nat Genet. 2017 May;49(5):659-665
pubmed: 28369038
Blood Adv. 2020 Nov 10;4(21):5343-5356
pubmed: 33125463
Methods Enzymol. 2019;629:465-492
pubmed: 31727254
Nature. 2017 Dec 21;552(7685):404-409
pubmed: 29236683
Immunity. 2000 May;12(5):547-56
pubmed: 10843387
Bioinformatics. 2019 Sep 1;35(17):2974-2981
pubmed: 30657870
Proc Natl Acad Sci U S A. 2020 Dec 22;117(51):32574-32583
pubmed: 33288689
Nature. 1988 Aug 4;334(6181):395-402
pubmed: 3043226
J Immunol. 2016 Jun 15;196(12):5005-13
pubmed: 27183615
Virology. 1998 Jan 5;240(1):158-67
pubmed: 9448700
Nat Med. 2001 Aug;7(8):913-9
pubmed: 11479623
Cell Rep Med. 2022 Mar 04;3(3):100557
pubmed: 35474751
Front Immunol. 2022 Jul 29;13:939394
pubmed: 35967295
Cell Rep. 2020 Feb 11;30(6):1910-1922.e5
pubmed: 32049020
Cell Mol Gastroenterol Hepatol. 2020;10(3):507-526
pubmed: 32361018
J Immunol. 2011 Dec 1;187(11):5568-76
pubmed: 22043009
Front Immunol. 2017 Oct 12;8:1267
pubmed: 29075258
Eur J Immunol. 1998 Jan;28(1):390-400
pubmed: 9485218
Virology. 2003 Oct 10;315(1):93-102
pubmed: 14592762
Blood. 2011 Aug 25;118(8):2138-49
pubmed: 21734237
Nat Rev Immunol. 2018 Jun;18(6):363-373
pubmed: 29520044
Nat Commun. 2019 Mar 4;10(1):1019
pubmed: 30833553
Front Immunol. 2022 Mar 24;13:851868
pubmed: 35401538
Immunity. 2015 Jan 20;42(1):95-107
pubmed: 25601203
J Virol. 2007 Feb;81(4):2002-11
pubmed: 17151096
J Immunol. 2008 Aug 1;181(3):2124-33
pubmed: 18641351
J Virol. 2008 Dec;82(23):11734-41
pubmed: 18829752

Auteurs

Michal Mark (M)

Department of Immunology, Weizmann Institute of Science, Rehovot, Israel.

Shlomit Reich-Zeliger (S)

Department of Immunology, Weizmann Institute of Science, Rehovot, Israel.

Erez Greenstein (E)

Department of Immunology, Weizmann Institute of Science, Rehovot, Israel.

Adi Biram (A)

Department of Immunology, Weizmann Institute of Science, Rehovot, Israel.

Benny Chain (B)

Division of Infection and Immunity, Department of Computer Science, University College London, London, United Kingdom.

Nir Friedman (N)

Department of Immunology, Weizmann Institute of Science, Rehovot, Israel.

Asaf Madi (A)

Department of Pathology, Tel-Aviv University, Tel-Aviv, Israel.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH